[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:p-tau217":3},{"name":4,"total":5,"recruiting":6,"trials":7},"p-tau217",5,3,[8,16,22,28,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07236190","Biomarker-based Trial of NPC-1 for Alzheimer's Pathology",[12],"Phase 2","RECRUITING","2026-08-26T02:18:05.435729Z","2026-07-05T05:32:16.676716Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07667478","NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE",[],"2026-08-26T02:17:39.048487Z","2026-07-05T03:45:20.370664Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07701161","Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device",[],"2026-08-26T02:18:32.765187Z","2026-07-19T19:36:05.083304Z",{"nct_id":29,"title":30,"phases":31,"status":33,"updated_at":34,"content_modified":35},"NCT06964230","A Phase 2b\u002F3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects",[32],"Phase 2\u002FPhase 3","NOT_YET_RECRUITING","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:27.249786Z",{"nct_id":37,"title":38,"phases":39,"status":41,"updated_at":42,"content_modified":43},"NCT06709014","A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD",[40],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T02:23:47.185024Z","2026-05-05T02:35:31.910668Z"]